Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction. However, there currently are no clinical indications for preferential use of ridogrel over aspirin. It is grouped under the following drug class(es): Antiplatelets. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Ridogrelum, Ibidel and R-68070. Its PubChem CID is 5362391.
Ridogrel
| CAS No | 110140-89-1 |
|---|---|
| Molecular Formula | C18H17F3N2O3 |
| Molecular Weight | 366.3 g/mol |
| Synonyms | 5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction.
The listed CAS number is 110140-89-1.
The listed molecular formula is C18H17F3N2O3.
The listed molecular weight is 366.3 g/mol.
5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid.
The source lists Ridogrelum, Ibidel and R-68070.